• In the past quarter, Trulieve Cannabis Corp. reported second-quarter 2026 sales of US$271 million, down from US$302.1 million a year earlier, with net loss widening to US$406 million and basic and diluted loss per share from continuing operations at US$2.10, compared with US$0.07 previously.
• Over the first half of 2026, sales softened to US$557.7 million from US$599.8 million while net loss expanded to US$403.6 million and loss per share from continuing operations rose to US$2.09, highlighting how quickly earnings have deteriorated despite only a moderate revenue decline.
• We’ll now explore how this sharp swing to a much larger quarterly net loss may affect Trulieve Cannabis’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Trulieve Cannabis Investment Narrative Recap

To own Trulieve, you need to believe its vertically integrated model can convert regulatory change and medical expansion into sustainable profits. The latest results, with a much larger net loss despite only modestly lower sales, sharpen the near term focus on earnings quality and cash generation. In the short term, the key catalyst remains federal rescheduling and associated tax relief, while the biggest risk is that rising costs and investments outpace revenue, keeping losses elevated.

Among recent announcements, the June 9 share buyback authorization of up to US$50 million or 5% of outstanding shares stands out beside this weak quarter. While not a recommendation, that plan sits awkwardly against a US$406 million Q2 loss and heightens questions about capital allocation, especially as Trulieve continues to invest in new markets like Georgia and Texas and in technology projects such as Project Hyper to support future catalysts.

Yet even if federal tax relief arrives, investors should still be aware of how ongoing pricing pressure could...

Trulieve Cannabis' narrative projects $906.7 million revenue and $339.0 million earnings by 2029. This requires an 8.2% yearly revenue decline and a $415.0 million earnings increase from -$76.0 million today.

Uncover how Trulieve Cannabis' forecasts yield a $19.42 fair value, a 122% upside to its current price.

Exploring Other Perspectives

Before this Q2 loss, the most pessimistic analysts still expected earnings to reach about US$250 million by 2029, but given the revenue decline and rising losses, you can see how opinions on timing, Texas and Georgia expansion, and overall risk could shift quite a bit from here.

Explore 3 other fair value estimates on Trulieve Cannabis - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Trulieve Cannabis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Trulieve Cannabis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Trulieve Cannabis' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.